INTRODUCTION
Allogeneic hematopoietic cell transplantation (allo-HCT) is an established treatment option for patients with hematological malignancies and is increasingly performed worldwide. The major side effect of allo-HCT is graft-versus-host disease (GvHD). Acute GvHD is characterized by activation, expansion and cytokine production of donor T cells (Tcs) that have interacted with host and donor antigen-presenting cells (APCs). 1 --3 Crucial events in this process is the migration of APCs toward sites where tissue damage has occures, the uptake of antigen and the presentation toward the donor Tcs. T-cell receptor (TCR) activation, downstream signaling and consecutive Tc expansion, cytokine production and cytolytic effector function are key events for the complex immunopathology that ultimately leads to the clinical picture of GvHD. 4 The non-receptor cytoplasmic tyrosine kinase spleen tyrosine kinase (Syk) has an important role in transmitting signals from a variety of cell surface receptors involved in the GvHD process including Toll-like receptor 4, 5 chemokin receptors, 6, 7 Fc receptors 8 and integrin signaling. 7, 9 Furthermore, Syk is present in thymocytes and mature Tc populations such as intraepithelial gd-Tc and naive ab-Tc pointing toward its role in Tcs. Intact Syk is required for extracellular signal-regulated kinase activation and nuclear factor of activated T-cell transcriptional activation. 10 Recognition of certain peptides requiers Syk activation for TCR signaling. 11 Syk is involved in Tc lineage commitment as it was shown in response to fungal signaling via Dectin for Th17 responses. 12 This could be relevant as Th17 responses were shown to be involved in GvHD. 13 The application of Syk inhibitors has been successfully tested in murine models of glomerulonephritis, 14 lupus 15, 16 and rheumatoid arthritis. 17 Although initial studies were performed with broader protein tyrosine kinase inhibitors such as Curcumin or Piceatannol, recently more specific Syk kinase inhibitors, such as Syk Inhibitor I to IV or R406, of which the orally bioavailable prodrug is R788 (Fostamatinib) have been developed and safely tested in humans. 18 Recent phase II clinical trials demonstrated that Fostamatinib treatment effectively improved response rates in patients with rheumatoid arthritis. 19, 20 Therefore, by using pharmacological inhibitors we aimed to delineate the relevance of Syk with respect to protection from GvHD, graft-versus-leukemia effects and anti-viral immune responses. , Thy-1.2) mice were purchased either from Charles River Laboratory (Sulzburg, Germany) or from the local stock of the animal facility at Freiburg University. Mice were used between 6 and 12 weeks of age and only female or only male donor/recipient pairs were used. The luciferase (luc) transgenic C57BL/6 (Thy1.1) mice have been described previously. 21 Animal protocols (G-08/102) were approved by the Regierungspräsidium Freiburg, Freiburg, Germany.
MATERIALS AND METHODS
Bone marrow (BM) transplantation model and histopathology scoring BM transplantation experiments were performed as described previously. 22 Briefly, recipients were injected intravenously (i.v.) with 5 Â 10 6 wt BM cells after lethal irradiation with 900 cGy. To induce aGVHD, CD4 þ and CD8 þ Tcs were isolated from donor spleen and enriched by positive selection with the MACS cell separation system (Miltenyi Biotec, Auburn, CA, USA) using anti-CD4 and anti-CD8 MicroBeads. CD4 þ /CD8 þ Tc purity was 490% as assessed by flow cytometry (data not shown). The following doses of CD4 þ /CD8 þ Tcs were given: 3 Â 10 5 (C57BL/6-BALB/c) or Figure 1 . Syk inhibition improves survival after allo-HCT. Allo-HCT was performed as described for the C57BL/6 into BALB/c combination.
(a) Survival of animals receiving BM alone or with Tcs and vehicle, Fostamatinib or 50 mg/kg cyclosporine A (CSA) is displayed. Survival is improved in the Fostamatinib group as compared with the vehicle (Po0.0001) and to the CSA-treated group (P ¼ 0.0003). The experiment was performed twice and the resulting survival data were pooled. (b) Representative colon sections of animals on day 7 after allo-HCT from the indicated groups are shown. Apoptotic cells are marked with an asterisk, and crypt abscesses are indicated by an arrow (original magnification Â 400). Histopathology was quantified as indicated in the methods part. The mean score ± s.d. is shown, representing 3 individual animals and 12 analyzed high power field per group. (c) Animals were killed on day 7 after allo-HCT, and serum was isolated from the indicated groups. The mean values for IL-6, IL-10, IFN-g, tumor necrosis factor (TNF) and IL-12p70 ± s.d. are displayed, representing three individual animals per group. (d) Splenocytes were isolated on day 3 after allo-HCT from BALB/c recipients and were stained for CD4, CD44 and CD62L. The quantification of naive T N , T EM and T CM among CD4 þ Tc population is shown as percentage ±s.d. The experiment was performed twice each time with at least four animals per group. (e) Left panel: neutrophils were measured in the peripheral blood of allo-HCT recipients treated with vehicle or Fostamatinib by a hematocytometer. The absolute neutrophil counts are shown per ml blood. The experiment was performed once with six mice per group. Right panel: mice were killed on day 30 after allo-HCT, and donor engraftment was analyzed by flow cytometry for the indicated immune cell types. The experiment was performed twice with at least six animals per group. 1 Â 10 6 (FVB/N-C57BL/6, BALB/c-C57BL/6) i.v. on day 0. For the studies on immune reconstitution 1 Â 10 5 Tcs (C57BL/6-BALB/c) were given. Slides of small bowel, large bowel, the liver and skin samples collected on day 7 were stained with Hematoxylin/Eosin and scored by an experienced pathologist (UVG and ASG) blinded to the treatment groups. GvHD severity was determined according to a previously published histopathology scoring system. 23 
Tumor models
To investigate graft-versus-leukemia activity of transferred donor Tcs, we used A20 luc B-cell leukemia that has been previously demonstrated to migrate primarily to the BM with secondary infiltration of spleen and other lymphoid organs when injected i.v. at the time of allo-HCT. 22 As a second model Burkitt luc cells were used. 24 Animals were injected either with A20 luc (BALB/c background, 2 Â 10 5 ) or with Burkitt luc (C57BL/6 background, 5 Â 10 4 ) i.v. 2 days before administration of the Tcs to allow the leukemia or lymphoma respectively to home and establish.
Murine cytomegalovirus (MCMV) model
To evaluate antiviral Tc responses the MCMV (Smith strain) was used. MCMV were produced by mouse embryonic fibroblasts tissue culture and 1 Â 10 5 pfu were injected intraperitoneally. For analysis of MCMV-specific Tcs, Tc phenotype and interferon (IFN)-g production MCMV was injected on day 30 after allo-HCT while for the survival studies the same dose was injected on day 14 to have a more aggressive course of disease as immune reconstitution was not complete at this time point. At day 28 after infection the mice were killed. The spleen was removed and used for flow cytometrybased analysis for MCMV-specific Tcs. phycoerythrin-conjungated major histocompatibility complex class I tetramers presenting the MCMV epitopes pp89 (H-2L d ) and M164 (H-2D d ) were generated in the Pircher laboratory as described 25 and were used for staining. 26 The livers and salivary glands were weighed, homogenized by sonication and stored at À80 1C. The virus load was determined by plaque assay on murine embryo fibroblasts.
Syk inhibitor
In vitro studies were performed with R406 (AstraZeneca, Wedel, Germany), a small molecule Syk inhibitor and the active form of Fostamatinib. R406 was dissolved in dimethyl sulfoxide (DMSO) and a final concentration of 4 mM was used in vitro. For in vivo studies, Fostamatinib (AstraZeneca), the oral prodrug of R406, was prepared in 0.1% carboxymethylcellulose sodium, 0.1% methylparaben and 0.02% propylparaben (reagents from Sigma-Aldrich, Munich, Germany), and administered orally twice daily to mice (30 mg/kg) for 10 days after allo-HCT and started at day À1 after allo-HCT. The same vehicle without Fostamatinib was administered to the animals in the control group.
In vivo bioluminsecence imaging
In vivo bioluminsecence imaging was performed as described previously. 27 Cytotoxicity assay A total of 2 Â 10 5 A20 or L1210 target cells were plated in 96-well plates. Effector Tcs, enriched from transplanted mice (C57BL/6-BALB/c) on day 14 after allo-HCT by depletion of non-CD3 þ Tcs (Miltenyi Biotec), were preincubated with 4 mM R406 or DMSO as control, added at the indicated ratio of target:effector cells and incubated for 6 h at 37 1C. Cells were stained with AnnexinV-fluorescein isothiocyanate and propidium iodide (PI) and analyzed by flow cytometry.
Chromium release CD4
þ /CD8 þ Tcs were plated in 96-well round bottom plates in triplicates and incubated with 2 Â 10 3 51 Cr-labeled A20 target cells at the indicated ratios, and the assay was performed as described previously. 28 Generation of BM-derived dendritic cells (DCs) BM-derived DCs (BM-DCs) were prepared as described, 29 except that interleukin (IL)-4 was not used. The BM-DCs were enriched by specific culture conditions 29 and were used on day 7 --8 with 90% purity, studied by flow cytometry using anti-CD11c.
Adoptive BM-DC transfer studies
To study donor type BM-DC migration 3 Â 10 6 APCs (C57BL/6 luc) were injected i.v. on day 0.
Antigen uptake by BM-DCs BM-DCs were preincubated with 4 mM R406 or DMSO (control) and exposed to Latex Beads-Rabbit immunoglobulin G-fluorescein isothiocyanate Complex (Cayman Chemicals, Hamburg, Germany) or Dextran fluorescein isothiocyanate as indicated in the data sheet. Flow cytometry was used to quantify antigen uptake.
Tc proliferation assay
For analysis of Tc proliferation in vitro CD4
þ Tcs from BALB/c mice were purified by positive selection with anti-CD4 magnetic microbeads (Miltenyi Biotec), labeled with 1 mM carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes, Eugene, OR, USA) as described previously 30 and exposed to allogenic BM-DCs from C57BL/6 mice or CD3/CD28 Dynabeads (Invitrogen, Darmstadt, Germany) at a dose of 5 ml/2 Â 10 5 Tcs for 96 h. For in vivo studies, allo-HCT was performed as described for the C57BL/6 into BALB/c combination except that CD4 þ /CD8 þ Tcs were labeled with 1 mM CFSE as described previously. 30 After preincubation with R406 (4 mM) or DMSO as control 1 Â 10
þ Tcs were injected per mouse. Mice were treated either with vehicle or Fostamatinib as described above, 1 day after allo-HCT Tc proliferation was analyzed. Tc expansion was measured by flow cytometry.
Cell migration assay
For migration studies, 24-well Transwell migration chambers (Costar and Corning, Corning, NY, USA) were used. A total of 5 Â 10 5 cells were allowed to migrate through a polycarbonate filter (pore size: 5 mm for Tcs and 3 mm for DCs) at 37 1C. For blockade of Syk protein cells were preincubated with R406 (4 mM) or DMSO as control for 1 h. CXCL12 (R&D Systems, Wiesbaden-Nordenstadt, Germany) was added to the medium and migration was analyzed as described previously. 24 Cytoskeletal changes in BM-DCs and Tcs F-actin formation was determined after R406 or control treatment by intracellular staining with anti-phalloidin-Alexa Fluor 488 (Molecular Probes, Carlsbad, CA, USA) for flow cytometric quantification. Before staining, cells were fixed and permeabelized with Foxp3 staining kit (eBioscience, Frankfurt, Germany).
Flow cytometry
All antibodies were purchased from BD Bioscience (Heidelberg, Germany), BioLegend, (eBioscience) and used as fluorescein isothiocyanate, phycoerythrin, Alexa647 or Pacific Blue conjugates. The following antibodies were used for cell surface molecules and flow-cytometric analysis: B220 (RA3-6B2), CD3 (17A2), CD4 (GK 1.5/RM4-5), CD8 (53-6. 
À according to a previous description. 31 Data were acquired with a CyanADP (Beckman Coulter, Krefeld, Germany) and then analyzed with FlowJo 7/8 software (Tree Star, Ashland, OR, USA).
In vivo cytotoxic T lymphocyte activity
In vivo cytotoxic T lymphocyte assays against allogeneic B cells (Bcs) were performed as described previously. 31 
Cytokine measurements
The levels of IL-6, IL-12, IL-10, monocyte chemotactic protein-1, tumor necrosis factor and IFN-g were analyzed from serum of BALB/c Targeting Syk for GvHD prevention F Leonhardt et al Quantification of neutrophils in the peripheral blood Neutrophils were measured in the peripheral blood of allo-HCT recipients using the automated hematology analyzer Advia 120 (Siemens, Eschborn, Germany).
Statistical analysis
Differences in animal survival (Kaplan --Meier survival curves) were analyzed by log-rank test. For comparison of proliferation of conventional Tc luc , cytokines, mean fluorescence and GvHD histopathology scores between experimental groups, the two-tailed Students t-test was used. If no equal variances between the groups could be assumed, Welch's correction of t-test was applied. A P-value o0.05 was considered to be statistically significant. (Figure 1c) . There was no significant difference in IL-12, IL-10 and tumor necrosis factor serum levels between the groups (Figure 1c ). These data indicate the protective effect of Fostamatinib on GvHD severity. In order to assess the donor Tc phenotype after allo-HCT and Syk inhibition we investigated the amount of naive (T N ), central memory (T CM ) and effector memory Tcs (T EM ). There was no difference between the vehicle and the Fostamatinib group with respect to these Tc populations (Figure 1d ). To clarify if Fostamatinib prolongs neutropenia after allo-HCT, we measured the neutrophil count in the peripheral blood of allo-HCT recipients treated with vehicle or Fostamatinib. The absolute neutrophil counts were not significantly different in the vehicle as compared with the Fostamatinib group and donor engraftment in multiple lineages was intact (Figure 1e ). (Figure 2b) . To delineate the kinetics of Syk phosphorylation during the process of Tc activation, we exposed CD4 þ /CD8 þ Tcs to CD3/CD28 beads. Serial analyses demonstrated a strong increase of Syk phosphorylation after stimulation (Figure 2c) . Addition of the Syk inhibitor R406 to the cultures reduced Syk phosphorylation significantly (Figure 2c ). These data indicate that Syk protein is increasingly phosphorylated after alloantigen exposure and in response to CD3/CD28-based stimulation of Tcs. The observation that this effect could be antagonized with R406 suggested the inhibitory activity of the substance on alloantigen-driven Tc activation. As STAT3 was reported to be critical for T-cell alloactivation and GvHD, we analyzed if STAT3 phosphorylation upon CD3/CD28 stimulation would be impacted by Syk inhibition. We observed no difference regarding STAT3 phosphorylation in the presence versus absence of R406 (data not shown).
RESULTS

Pharmacological Syk inhibition with
Fostamatinib reduces acute GvHD Daily treatment with the orally available Syk inhibitor Fostamatinib for 10 days
Tc expansion is diminished when Syk phosphorylation is inhibited
To analyze regulatory Tcs after allo-HCT and Syk inhibition we investigated the amount of CD4 þ Foxp3 þ regulatory Tcs in the spleen. There was no difference between the vehicle and the Fostamatinib-treated group (Figure 2d ). There was also no difference in the abundance of Th17 or Th1 Tcs in the Fostamatinib as compared with the vehicle group (Figure 2d ). Reduced donor Tc expansion observed in the Syk inhibitor exposed Tc group by bioluminsecence imaging was confirmed by a CFSE-based assay on reisolated Tcs (Figure 2e ). In addition to the Tc proliferation, migration and cytoskeletal organization is affected by Syk inhibition As Tc proliferation and migration toward inflamed sites are crucial for Tc-mediated immunopathology during GvHD we analyzed these key features in vitro. Tc expansion in response to allogeneic DCs or CD3/CD28 beads was significantly reduced when Syk was inhibited as shown for a representative CFSE dilution assay and in the histogram for the percentage of expanded Tcs (Figures 3a and b) without an impact on Tc viability (Figure 3c ). Fostamatinib treatment did also not induce apoptosis in Tcs in vivo as shown for the frequency of Caspase 3 þ Tcs (Figure 3d ). Tc migration in response to CXCL12 was significantly lower when Syk was inhibited ( Figure 3e ).
As interference with Syk signaling may lead to a disruption of the actin cytoskeleton, we next characterized alterations in the cytoskeletal assembly using flow cytometry. CD4 þ /CD8 þ Tcs displayed increased phalloidin stain when stimulated with CD3/CD28 beads, indicative for active actin cytoskeletal rearrangements (Figure 3f) . 32 The observed effect of both stimuli on actin cytoskeletal rearrangements was antagonized by R406 although it did reach significance only for the CD3/CD28 (Figure 3f ). On the basis of these data expansion and migration as two major functions of Tcs were affected by Syk inhibition.
Graft-versus-leukemia effects are preserved when Syk is inhibited Inhibition of Tc function can be detrimental after allo-HCT as rejection of residual leukemia cells is dependent on intact killing mechanisms. We observed that Tcs that were isolated from allo-HCT recipients, treated with Fostamatinib or vehicle as control for 10 days were still able to exert cytotoxicity against allogeneic leukemia and lymphoma cells (Figure 4a ). Cytolytic activity of Tcs isolated from Fostamatinib-or vehicle-treated allo-HCT recipients against allogeneic A20 target cells was determined by chromium release assay and no significant difference was observed (Figure 4b ). Also the degranulation marker CD107a was found at comparable levels in Tcs isolated from allo-HCT recipients treated with Fostamatinib as compared with vehicle ( Figure 4c ). To evaluate graft-versus-leukemia activity the established A20 luc Bc leukemia model was used. 30 The leukemia signal on day 0, 2 h after transfer was comparable in all groups (Figure 4d) . By day 9, leukemia growth was blocked in the mice receiving Tcs independent of treatment with vehicle or Fostamatinib (Figure 4d ). The group that received Tcs and Fostamatinib had significantly improved survival as compared with all other groups ( Figure 4e ). Fostamatinib had no direct effect on the growth of the highly aggressive A20 Bc leukemia in vivo (Figure 4d ). Comparable survival was seen in a second tumor model using Burkitt lymphoma cells (Figure 4f ). Flow cytometry-based quantification of the B220 þ A20 leukemic cells in the BM indicated that all groups receiving Tcs cleared the tumor cells independent of Fostamatinib treatment (Figure 4g ). By using a previously described model system for in vivo cytolysis of allogeneic Bcs, 31 we found that cytolytic function of donor Tcs against allogeneic Bcs was intact (Figure 4h ). These data indicate that Syk inhibition may not affect cytotoxicity, which is crucial for anti-leukemia immunity after allografting.
Fostamatinib treatment does not interfere with anti-MCMV immunity As reactivation of CMV in the immunodeficient patient after allo-HCT is a significant clinical problem, we next studied whether Fostamatinib-mediated immune modulation would interfere with the generation of murine CMV (MCMV)-specific Tc clones. The frequency of CD8 þ Tcs in the spleen was comparable in all investigated groups on d58 when animals were killed. Markers reported to be downregulated on Tcs upon viral infection including CD62L 33 and CD27 (ref. 34) declined as compared with non-infected controls (Figure 5a ). KLRG1, which was reported to increase after viral infection 35 increased independently of Fostamatinib treatment (Figure 5a) . In a further step we assessed the frequency of CD8 þ Tcs specific for the MCMV peptides pp89 or M164 by tetramer staining and found that the frequency of MCMV-specific Tcs in the spleen did not differ significantly regardless of Fostamatinib treatment (Figure 5b ). Almost all tetramer-positive cells also expressed KLRG1, which was previously shown to be a marker for proliferated cells. 35 The frequency of pp89 or M164 by tetramer-positive CD8
þ Tcs was 1% in uninfected BM controls, indicating that this level represents the unspecific staining of the tetramers (Figure 5b ). We detected a comparable MCMV peptide specific IFN-g production by CD8
þ Tcs in both groups (Figure 5c ). The MCMV viral load in the salivary glands of both groups was comparable and there was no MCMV detectable in the liver of the infected animals (Figure 5d) . Previous work had shown that the salivary glands are an immune privileged site where MCMV persist. 36 Survival of MCMV infected allo-HCT recipients was not significantly different in the group treated with Fostamatinib as compared with vehicle-treated group (Figure 5e ).
Overall, these data indicate that anti-viral immunity was not affected by Fostamatinib treatment.
Syk inhibition interferes with enhanced expression of costimulatory molecules on DCs in response to lipopolysaccharide (LPS) APCs are have a key role in the process of GvHD development. During the early phase of GvHD LPS is a major pathogenic factor that enhances GvHD and leads to the activation of DCs. 37 Therefore, we evaluated the effects of Syk signaling in unstimulated and LPS-stimulated DCs. LPS enhanced expression of the costimulatory molecules CD80, CD86, CD40 and major histocompatibility complex class I and II. Addition of R406 significantly reduced CD80 and CD86 expression on the surface of LPSstimulated DCs (Figure 6a) . Additionally we were able to detect a difference of CD80 expression on recipient DCs in vivo 24 h after allo-HCT after Fostamatinib treatment, but not for CD86 (Figure 6b ). This could be due to the highly proinflammatory microenvironment in the spleen following irradiation that decreased the effects for CD86 we had seen in vitro. Phagocytosis ( Figure 6c ) and endocytosis ( Figure 6d ) remained intact when DCs were exposed to R406. These data indicate that Syk has a central role in the LPS-induced upregulation of the costimulatory molecules CD80 and CD86, which were shown to be relevant for GvHD pathophysiology. 38 In vivo DC migration is impaired when Syk phosphorylation is inhibited As Syk signaling has an important role in the cytoskeletonorganizing processes in different cell populations, 39 we next evaluated the impact of the Syk inhibitor on cytoskeleton rearrangements and migratory function of DCs. R406 potently reduced the migration of DCs toward a CXCL12 chemokine gradient (Figure 7a ). Although DCs stimulated with LPS showed increased phalloidin stain indicative for active actin rearrangements this increase was blocked by R406 consistent with a defect in cytoskeletal assembly (Figure 7b ). To verify whether these profound effects on DC migration were reproducible in vivo we tracked luc transgenic donor type DCs (DC luc ) that were co-infused with the BM graft and observed their accumulation in secondary lymphoid organs in a pattern as reported previously. 40 Treatment with Fostamatinib significantly reduced DC accumulation as shown representatively for day 4 after allo-HCT (Figure 7c) . Quantification of luc signal derived from DCs that had reached the cervical lymph nodes after allo-HCT indicated significantly reduced accumulation when Syk function was blocked by Fostamatinib in comparison with vehicle treatment (Figure 7c ). The bioluminsecence imaging data were verified by fluorescence-activated cell sorting analysis for DCs (CD11c/I-A b ; data not shown). These results indicate that Fostamatinib reduces the migratory activity of DCs in vivo.
DISCUSSION
Suppression of the immune response by targeting key signaling events in lymphocytes such as nuclear factor of activated T-cell signaling by cyclosporin A has revolutionized transplantation medicine. 41 However, despite improved outcome of allo-HCT, GvHD grade 2 --4 remains a major factor causing high treatmentrelated mortality. 42 In contrast to the tradition of interfering with lymphocyte function by immunosuppressive drugs recent evidence support the concept that DCs are attractive targets for pharmacological interventions as they are key regulators of GvHD. 43 We therefore hypothesized that agents that target both Tc activation and allostimulatory functions of DCs may have a strong therapeutic potential in GvHD.
In this study, we show that treatment with the Syk inhibitor Fostamatinib potently modulated murine Tc and DC functions and interfered with GvHD while anti-leukemia and anti-MCMV effects were preserved. Activation of Syk was observed in CD3 þ Tcs reisolated from allo-HCT recipients. Fostamatinib was more potent at reducing aGvHD lethality than cyclosporin A when given at a clinically used dosage.
Recent data indicate that T-cell non-Hodgkin's lymphoma cell proliferation is dependent on Syk, 44 and that many of the same signaling pathways that are active in malignant lymphoma cells where Syk inhibitors are already applied clinically 45 are also relevant for the activation of non-malignant lymphocytes. To address the mechanism for the potent protective in vivo effects against Tc-mediated GvHD, we first turned toward Tcs and observed reduced proliferative allo-responses in vitro that were consistent with the reduced expansion of Tc luc documented in vivo. Although Tc expansion was significantly reduced in the group treated with Fostamatinib, the phenotype, cytokine production and cytolytic activity of Tcs were comparable to the vehicle group. R406 was shown to be most potent at inhibiting Syk. 18 However, R406 is a 5 --100-fold less potent inhibitor of other kinases, such as Flt-3, c-Kit, Lck and Janus kinase-1 and 3, which are involved in the IL-2-induced primary Tc activation pathway. 18 We had studied the effects of R406 at concentrations that were below those described for the inhibition of Janus kinasedependent anti CD3/CD28 TCR-induced IL-2 production at 448 nM 18 and found no inhibitory effect. At the higher doses a certain degree of inhibition of other kinases although being less Figure 6 . Upregulation of CD80 and CD86 on BM-DCs in response to LPS requires functional Syk. (a) BM-DCs were exposed to LPS (1 mg/ml) and R406 (4 mM) or DMSO as control for 24 h. Surface expression of the indicated molecules was measured. Mean fluorescence intensity (MFI) ± s.d. is displayed for one representative of five independent experiments, each performed in triplicates. Right panel: representative histograms for CD80 and CD86 on DCs measured by flow cytometry for the indicated groups are shown. (b) Allo-HCT was performed as described for the C57BL/6 into BALB/c model with at least three animals per group. After 24 h allo-HCT splenocytes were isolated from the indicated groups and recipient DCs (CD11c þ /I-A d þ ) were analyzed for CD80 and CD86 expression by flow cytometry. Left panel: MFI ±s.d. for CD80 or CD86 expression is displayed for one representative of two independent experiments, each performed with at least three animals per group. Right panel: representative histograms for CD80 and CD86 on recipients DCs measured by flow cytometry for the indicated groups are shown. (c) BM-DCs were exposed to IgG-fluorescein isothiocyanate (FITC) (100 ml/ml) and R406 (4 mM) or DMSO as control where indicated. IgG-FITC uptake was measured after 24 h by flow cytometry. MFI ± s.d. for FITC of BM-DCs is displayed for one representative of three independent experiments, each performed in triplicates. (d) BM-DCs were exposed to Dextran-FITC (100 ml/ml) and R406 (4 mM) or DMSO as control where indicated. Dextran-FITC uptake was measured after 24 h by flow cytometry. MFI ±s.d. for FITC of BM-DCs is displayed for one representative of three independent experiments, each performed in triplicates.
potent than for Syk inhibition is conceivable. Although it was shown that ZAP-70 is the key molecule for TCR signaling, 46 Syk also associates with TCR subunits and undergoes tyrosine phosphorylation after TCR stimulation, 47 which suggests its role during Tc activation. Furthermore, not only activation and expansion but also migration of Tc is a major requirement for GvHD. Consistent with a role of Syk in cell migration, we observed that Tc migration was affected by Syk inhibition. Mechanistically, we could demonstrate that actin rearrangement in response to TCR stimulation was significantly reduced when Syk was inhibited. However, a complete blockade of Tc function after allo-HCT would be detrimental as Tcs are required for anti-leukemia and antipathogen immune responses. We studied the impact of Fostamatinib on anti-leukemia and anti-MCMV immunity and found that both were intact. Anti-MCMV reactive Tcs were generated independent of Fostamatinib treatment and MCMV was eliminated from the liver.
Our data indicate that CD8 þ Tc-mediated cytolytic activity is intact despite Fostamatinib treatment, while alloreactive Tc expansion is impaired. Furthermore, the effects of Fostamatinib were not restricted to the Tc compartment. DC migration and costimulatory molecule upregulation in response to LPS were blocked by Fostamatinib treatment. By this way GvHD severity was reduced to a certain degree while alloreactivity and intact cytolytic activity of CD8 Tcs were maintained and still capable of exerting tumor control.
Different immunomodulatory agents, including rapamycin and IL-10, alter the phenotype of DCs by reducing the expression of costimulatory molecules. 40, 48, 49 We found that Syk inhibitor treatment reduced the upregulation of CD80 and CD86 in response to LPS, rendering this cell population more tolerogenic. Beside the effects of Syk inhibition on the stimulatory properties of DCs, we also found that intact Syk activation was required for actin remodeling and migration of this cell population in vitro and in mice that had undergone allo-HCT. This is consistent with previous reports indicating that Syk is critical for integrin signaling to the cytoskeleton, 50 cell migration 51 and the recruitment toward inflammatory sites. 52 As DCs need to migrate toward secondary lymphoid organs and present antigen to effectively prime the allogeneic Tcs, interference with this step may block the pathogenesis of GvHD at an early stage. Beside its relevance for cell migration, the integrity of the actin cytoskeleton is essential for efficient formation of the immunological synapse, 53 which may be an additional mechanism of how Syk inhibition could impact DC --Tc interaction.
Despite these effects on the Tc and APC compartment, Syk inhibition did not suppress the cytotoxic T lymphocyte responses to allogeneic tumor targets in two different tumor models. On the basis of the antineoplastic effects of Fostamatinib in non-Hodgkin lymphomas, 44, 45 Syk inhibition may even be synergistic with allo responses and render leukemias more susceptible to Tc-mediated cytotoxicity.
Consistent with our studies in the GvHD model, preclinical studies on Syk inhibition in models of autoimmunity 14 --16 demonstrated its immunomodulatory effect. In clinical trials Syk inhibitions was effective in immune thrombocytopenic purpura 54 and rheumatoid arthritis. 19, 20 In summary, we demonstrate that pharmacological Syk inhibition targets several key events of GvHD pathogenesis including expansion and migration of Tcs as well as costimulation by and migration of DCs. Importantly, cytolytic effector function of cytotoxic T lymphocyte against leukemia cells and anti-MCMV immunity were preserved despite Syk inhibition. Our study provides a rationale for the application of Syk inhibitors as a potential approach to selectively prevent GvHD without impairing leukemia-specific T-cell immunity.
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